Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 335

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Conditions:   Thyroid Carcinoma;   Thyroid Cancer;   Thyroid Cancer, Follicular;   Thyroid Cancer (Follicular Cell);   Thyroid Cancer, Papillary;   BRAF V600E Mutation Positive
Interventions:   Diagnostic Test: I-124 PET/CT lesion dosimetry;   Drug: Vemurafenib;   Drug: Copanlisib
Sponsor:   Memorial Sloan Kettering Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 9, 2020 / by / in
Comments